Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.19
Views: 834

Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK

Dr Stefanie Fischer speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about a retrospective analysis looking at outcomes of clinical stage I nonseminoma patients who relapse after adjuvant chemotherapy with BEP.

She reports that a high rate of late and subsequent relapses was seen, with 29% occurring more than 3 years after adjuvant treatment and one even 25 years after.

Prof Fischer explains that they used a negative selection and only focused on those who relapsed, so this analysis does not affect the general very good outcome seen from adjuvant BEP.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation